跳到正文
原文
MedPage Today·· 13 天前精选AI 评分75

FDA 调查 Zolgensma 与严重恶性肿瘤风险关联

FDA Investigating Serious Malignancy Risk Linked to Gene Therapy

AI 导读

Novartis 确认 Zolgensma 已报告九例肿瘤病例,其中两个病例显示病毒载体 DNA 集成到患者 DNA 中。FDA 正在调查该风险,涉及多个 SMA 患者。

推荐理由

报道了 FDA 正在调查 Zolgensma 与肿瘤风险的关联,涉及多个案例,提醒业界关注基因疗法的安全性。

正文

— Novartis acknowledges reports in SMA patients treated with Zolgensma

by Judy George, Deputy Managing Editor, MedPage Today

November 6, 2026 • 3 min read

Drugmaker Novartis acknowledged Thursday that there have been nine reports of tumors in children treated with its gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA).

Two of the tumor cases were linked to the drug, the company said.

Zolgensma, an adeno-associated virus (AAV) vector-based gene therapy, was approved in 2019 to treat pediatric patients under 2 years of age with SMA and bi-allelic SMN1 mutations.

"Since first approval in 2019, Novartis has received 9 reports of tumors in patients previously treated with Zolgensma," a Novartis spokesperson wrote in an email to MedPage Today.

"Of those, two cases to date have shown evidence of vector DNA integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored," the spokesperson continued. "In each case, we timely and appropriately notified health authorities and will continue to work with them on next steps."

The spokesperson did not say when tumors may have developed in the other seven cases, or when they were identified.

SMA is caused by reduced levels of the survival motor neuron (SMN) protein due to deletions or mutations in the SMN1 gene. A nearly identical gene, SMN2, produces low levels of functional SMN protein.

Onasemnogene abeparvovec uses an AAV vector to replace the SMN1 gene. Its prescribing information notes a theoretical risk of tumorigenicity from the integration of AAV vector DNA into the genome.

"The potential risk of tumors due to vector integration is currently included in the Zolgensma prescribing information," Novartis said.

Advocates recently raised concerns on social media after learning from their doctors that Novartis had received reports of tumors in patients treated with the gene therapy. SMA Europe, an umbrella organization of SMA patient groups in Europe, acknowledged the reports in a news release early Thursday.

"We understand that the relevant regulatory authorities are actively involved and are currently assessing the available evidence and determining what further steps may be needed," SMA Europe stated. "We trust in the regulatory processes established to evaluate safety signals and to take the necessary measures to protect patients and ensure the continued safety of medicines on the market."

In the U.S., the Muscular Dystrophy Association (MDA) said it was "seeking additional information, reviewing the available scientific and safety data with clinical and research experts, and has reached out to Novartis."

The MDA added that "limited information is available currently about the timing of events, nature of the tumors, and any future monitoring of treated individuals that may become appropriate."

A 2023 case report described a 16-month-old boy with SMA who was diagnosed with an epithelioid neoplasm of the spinal cord 14 months after receiving onasemnogene abeparvovec; the finding was considered inconclusive. A 2025 case report detailed a pilocytic astrocytoma in a child with SMA treated with onasemnogene abeparvovec; a molecular analysis suggested tumorigenesis was causally independent of the gene therapy.

Earlier this year, researchers identified vector integration in a brain tumor in a 5-year-old boy with severe mucopolysaccharidosis type I (Hurler syndrome) who received another AAV gene therapy, describing the case in the New England Journal of Medicine.

More than 6,000 patients have been treated with Zolgensma in clinical trials, managed access programs, and commercial treatment, Novartis said. "As part of Novartis' ongoing commitment to monitoring the safety of our medicines, we continually evaluate new safety information and assess all reported cases," the company added.

The tumor reports are not the first controversy involving Zolgensma. Soon after the therapy was approved, the FDA criticized the Novartis AveXis unit over data manipulation that affected the accuracy of animal product-testing results.

来源:MedPage Today · medpagetoday.com